Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 13:00
Regulatory News Service
Förändring i Sobis styrelse
Swedish 132.4 KB
2025-10-21 13:00
Board/Management Information
Change in the Sobi Board of Directors
English 98.8 KB
2025-10-20 08:00
Quarterly Report
Swedish 3.8 MB
2025-10-20 08:00
Quarterly Report
English 4.1 MB
2025-10-19 20:30
Earnings Release
Sobi meddelar reviderade helårsutsikter och tidigarelägger publiceringen av del…
Swedish 206.4 KB
2025-10-19 20:30
Earnings Release
Sobi announces revised full year outlook and advances publication of the Q3 202…
English 174.2 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 137.5 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 126.9 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 100.2 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 97.9 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Swedish Orphan Biovitrum

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Katy Mazibuko Other Sell 1,500 480,000.00 SEK
2024-08-30 Katy Mazibuko Other Sell 269 86,012.75 SEK
2024-08-12 Sara Karlsson Other Buy 86 23,391.79 SEK
2024-07-25 Mahmood Ladha Other Buy 84,585 12,360,406.05 SEK
2024-07-23 Mahmood Ladha Other Sell 84,585 24,614,235.00 SEK
2024-06-10 Christin Wesström Other Other 7,433 N/A
2024-06-03 Guido Oelkers Other Buy 117,332 23,965,061.00 SEK
2024-05-30 Guido Oelkers Other Sell 117,332 32,090,302.00 SEK
2024-05-15 Henrik Stenqvist Other Buy 72,534 14,815,069.50 SEK
2024-05-13 Henrik Stenqvist Other Sell 72,534 20,766,484.20 SEK

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.